Lymphoma, B-Cell: all 1,415 studies
Page 9 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell LymphomaCompletedNCT04695366
- A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's LymphomaActive, not recruitingNCT04693676Phase 1
- CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell LymphomaCompletedNCT04690192Phase 1/2
- Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell MalignanciesStatus unknownNCT04684472Phase 1
- Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell LymphomaSuspendedNCT04668365Phase 2
- Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)WithdrawnNCT04665115Phase 2
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Active, not recruitingNCT04662255Phase 3
- A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's LymphomaCompletedNCT04655677Phase 1
- CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04649983Phase 1/2
- Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and LymphomaStatus unknownNCT04648475Phase 1/2
- CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)Active, not recruitingNCT04637763Phase 1
- Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaWithdrawnNCT04635683Phase 1
- FT819 in Subjects With B-cell MalignanciesActive, not recruitingNCT04629729Phase 1
- Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin LymphomaStatus unknownNCT04626908Phase 1/2
- A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab EraStatus unknownNCT04624971
- A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab VedotinStatus unknownNCT04624893
- Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 YearsStatus unknownNCT04622579Phase 2
- A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）Status unknownNCT04610970Phase 2
- Lenalidomide and Low-dose Cyclophosphamide for MALT LymphomaStatus unknownNCT04604028Phase 2
- Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell LymphomaStatus unknownNCT04600947Phase 2
- A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCLActive, not recruitingNCT04594798Phase 2
- A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT04594642Phase 1
- CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaCompletedNCT04578600Phase 1
- A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride InjectionCompletedNCT04569838Phase 2
- 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT04566978Early Phase 1
- A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 MalignanciesWithdrawnNCT04556266Phase 1
- Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell LymphomaStatus unknownNCT04544059Phase 2
- POLA+BR for Relapsed or Refractory DLBCLWithdrawnNCT04535102Phase 2
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Active, not recruitingNCT04529772Phase 3
- Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaActive, not recruitingNCT04526834Phase 1
- Telemedicine for Early Detection of Cytokine Release Syndrome and NeurotoxicityWithdrawnNCT04503538Not applicable
- Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLLStatus unknownNCT04502394Phase 1/2
- YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical TrialStatus unknownNCT04500561Phase 1/2
- Long-term Follow-up Study for Patients Treated With CLBR001 CAR-TCompletedNCT04488354Phase 1
- An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells InjectionStatus unknownNCT04486872Phase 1
- Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCLStatus unknownNCT04476459Phase 1/2
- Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04460248Phase 2
- Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)WithdrawnNCT04456023Phase 2
- CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell MalignanciesCompletedNCT04450069Phase 1
- An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to TreatmentActive, not recruitingNCT04447716Phase 1
- A Study of ICP-022 in Patients With R/R DLBCLCompletedNCT04438005Phase 2
- Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's LymphomasStatus unknownNCT04435743
- Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell LymphomaStatus unknownNCT04432402Not applicable
- Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell LymphomaStatus unknownNCT04425824Phase 2
- Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell LymphomaStatus unknownNCT04423549
- Retreatment With CTL019/CTL119WithdrawnNCT04419909Phase 1
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1CompletedNCT04418141Phase 1
- A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHLStatus unknownNCT04412174Early Phase 1
- Vaccine Responsiveness After CAR-T Cell TherapyCompletedNCT04410900Phase 1
- Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell TherapyCompletedNCT04409314
- CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell LymphomaStatus unknownNCT04381741Phase 1
- Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCLCompletedNCT04354402
- TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaCompletedNCT04323657Phase 1/2
- A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL SubjectsCompletedNCT04317885Phase 1
- Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's LymphomasTerminatedNCT04305444Phase 2
- A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell LymphomaActive, not recruitingNCT04304040Phase 1/2
- CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHLStatus unknownNCT04303247Early Phase 1
- Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell LymphomaStatus unknownNCT04296461Phase 1
- Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic LeukemiaStatus unknownNCT04289220Phase 1
- CD19/CD20 Dual-CAR-T in B-cell Lymphoma PatientsCompletedNCT04260932Phase 1
- Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell LymphomaStatus unknownNCT04250324Phase 1
- Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell LymphomaStatus unknownNCT04246359Phase 2
- A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)Active, not recruitingNCT04245839Phase 2
- FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesTerminatedNCT04245722Phase 1
- Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)CompletedNCT04240808Phase 1
- Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL)Status unknownNCT04237168
- A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT04231747Phase 1
- Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin LymphomaWithdrawnNCT04220008Phase 2
- CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell MalignanciesActive, not recruitingNCT04214886Phase 1
- PD1-CD19-CART in Patients With r/r B-cell LymphomaCompletedNCT04213469Not applicable
- Treatment of Hematological Malignancy With Novel CAR-T Cells.Status unknownNCT04191941Early Phase 1
- Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell LymphomaStatus unknownNCT04173455Phase 1
- The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin LymphomaStatus unknownNCT04169932Early Phase 1
- Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell LymphomaStatus unknownNCT04163302Phase 2
- Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell LymphomaActive, not recruitingNCT04161248Early Phase 1
- TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin LymphomaTerminatedNCT04161118Phase 2
- The Clinical Implications of Immune Checkpoint Pathways in PCNSLCompletedNCT04158128
- Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular LymphomaTerminatedNCT04156828Phase 1
- R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHLStatus unknownNCT04152577Phase 4
- Lenalidomide Monotherapy in R/R DLBCLCompletedNCT04150328
- Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)WithdrawnNCT04148742Phase 1/2
- A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell TherapyActive, not recruitingNCT04148430Phase 2
- CAR-37 T Cells in Hematologic MalignanciesCompletedNCT04136275Phase 1
- ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose ChemotherapyCompletedNCT04121507Phase 2
- ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell LymphomaStatus unknownNCT04112238
- A Study of MIL62 in Treatment of CD20 Positive B-cell LymphomasCompletedNCT04103905Phase 1
- Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin LymphomaCompletedNCT04094142Phase 2
- CD22-CAR T Cells in Children and Young Adults With B Cell MalignanciesCompletedNCT04088864Phase 1
- Study of A-319 in Patients With Relapsed or Refractory B-cell LymphomaStatus unknownNCT04056975Phase 1
- QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell LymphomaWithdrawnNCT04052061Phase 1
- ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)Active, not recruitingNCT04049513Phase 1
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT04045028Phase 1
- CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.Status unknownNCT04037566Phase 1
- A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T TherapyCompletedNCT04036019Phase 1
- γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)Status unknownNCT04028440Early Phase 1
- CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaStatus unknownNCT04026100Phase 1
- Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.Status unknownNCT04023916Phase 2
- FT516 in Subjects With Advanced Hematologic MalignanciesTerminatedNCT04023071Phase 1
- BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)CompletedNCT04018248Phase 1
- Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell MalignanciesStatus unknownNCT04008251Phase 1